Buying another company should never be out of the realm of possibility. Especially if it can contribute to the bottom line and is cash accretive immediately. For instance if a syringe company or such. There are many more that also fit that category. But not at this time. Price, working relationship, how it alines with the companies goals all have to be accounted for. The obvious problem is there are too few people in this company to do too many jobs so acquiring another company would take away from its multiple goals in the near future. Acquiring Patterson‘s company doesn’t fit any criteria that Cytodyn has put forth as goals in the next year and definitely would not be accretive to its bottom line